ESSA Pharma's Business Combination with XenoTherapeutics: Key Dates and Financial Analysis

ESSA Pharma (EPIX) is undergoing a business combination with XenoTherapeutics, a biotechnology non-profit. The Supreme Court of British Columbia has sanctioned key dates for the transaction, including a special meeting on October 3. ESSA Pharma operates in the biotechnology sector, focusing on small-molecule drugs for castration-resistant prostate cancer. The company's financial metrics reveal a challenging landscape, with no revenue and a low Piotroski F-Score. Despite this, the stock is trading at a significant discount to its book value and has been heavily oversold.

ESSA Pharma Inc. (EPIX), a biotechnology company focused on developing small-molecule drugs for castration-resistant prostate cancer, has received an amended Interim Order from the Supreme Court of British Columbia. This order approves key dates for the company's business combination with XenoTherapeutics Inc., a non-profit biotechnology company ESSA Pharma Inc. Provides Update on its Application to the Supreme Court of British Columbia for Amended Interim Order^[1].

The amended Interim Order sets the following significant dates:
- A special meeting of the holders of common shares, optionholders, and warrantholders on October 3, 2025.
- The deadline for delivering notices of dissent on October 1, 2025.
- The Court hearing date for the approval of the Arrangement on October 7, 2025.
- The deadline for responses from persons intending to attend the October 7th hearing also on October 3, 2025.

The special meeting will be held online via a live interactive webcast at https://meetnow.global/MHPMJ4R. ESSA Pharma has filed supplemental proxy materials reflecting the revised terms of the transaction on September 24, 2025, on its profile on EDGAR at www.sec.gov and on SEDAR+ at www.sedarplus.ca ESSA Pharma Inc. Provides Update on its Application to the Supreme Court of British Columbia for Amended Interim Order^[1].

Despite the challenging financial landscape, with no revenue and a low Piotroski F-Score, ESSA Pharma's stock is trading at a significant discount to its book value and has been heavily oversold. The company is currently undergoing a business combination with XenoTherapeutics, which aims to advance xenotransplantation through scientific research, clinical development, and public education ESSA Pharma Inc. Provides Update on its Application to the Supreme Court of British Columbia for Amended Interim Order^[1].

Investors and securityholders are urged to read the definitive proxy statement and any other relevant documents filed with the SEC or SEDAR+ for more information about the proposed transaction. The proxy statement is available on the Company's profile on EDGAR at www.sec.gov and on SEDAR+ at www.sedarplus.ca ESSA Pharma Inc. Provides Update on its Application to the Supreme Court of British Columbia for Amended Interim Order^[1].